167 related articles for article (PubMed ID: 7572348)
41. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
Harker WG; Slade DL; Drake FH; Parr RL
Biochemistry; 1991 Oct; 30(41):9953-61. PubMed ID: 1655025
[TBL] [Abstract][Full Text] [Related]
42. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Ellis AL; Nowak B; Plunkett W; Zwelling LA
Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
[TBL] [Abstract][Full Text] [Related]
43. Quantitative immunofluorescence and immunoelectron microscopy of the topoisomerase II alpha associated with nuclear matrices from wild-type and drug-resistant chinese hamster ovary cell lines.
Valkov NI; Gump JL; Sullivan DM
J Cell Biochem; 1997 Oct; 67(1):112-30. PubMed ID: 9328845
[TBL] [Abstract][Full Text] [Related]
44. Genistein resistance in human leukaemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase II beta isoform.
Markovits J; Junqua S; Goldwasser F; Venuat AM; Luccioni C; Beaumatin J; Saucier JM; Bernheim A; Jacquemin-Sablon A
Biochem Pharmacol; 1995 Jul; 50(2):177-86. PubMed ID: 7632161
[TBL] [Abstract][Full Text] [Related]
45. SUMO-1 conjugation to human DNA topoisomerase II isozymes.
Mao Y; Desai SD; Liu LF
J Biol Chem; 2000 Aug; 275(34):26066-73. PubMed ID: 10862613
[TBL] [Abstract][Full Text] [Related]
46. Etoposide-induced DNA cleavage in human leukemia cells.
Edwards CM; Glisson BS; King CK; Smallwood-Kentro S; Ross WE
Cancer Chemother Pharmacol; 1987; 20(2):162-8. PubMed ID: 2822274
[TBL] [Abstract][Full Text] [Related]
47. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Rappa G; Lorico A; Sartorelli AC
Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
[TBL] [Abstract][Full Text] [Related]
48. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
Fortune JM; Osheroff N
Prog Nucleic Acid Res Mol Biol; 2000; 64():221-53. PubMed ID: 10697411
[TBL] [Abstract][Full Text] [Related]
49. DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS.
Gao H; Yamasaki EF; Chan KK; Shen LL; Snapka RM
Mol Pharmacol; 2003 Jun; 63(6):1382-8. PubMed ID: 12761349
[TBL] [Abstract][Full Text] [Related]
50. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
[TBL] [Abstract][Full Text] [Related]
51. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
52. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
[TBL] [Abstract][Full Text] [Related]
53. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
Cornarotti M; Tinelli S; Willmore E; Zunino F; Fisher LM; Austin CA; Capranico G
Mol Pharmacol; 1996 Dec; 50(6):1463-71. PubMed ID: 8967966
[TBL] [Abstract][Full Text] [Related]
54. Nuclear matrix attachment regions and topoisomerase II binding and reaction sites in the vicinity of a chicken DNA replication origin.
Razin SV; Vassetzky YS; Hancock R
Biochem Biophys Res Commun; 1991 May; 177(1):265-70. PubMed ID: 1645958
[TBL] [Abstract][Full Text] [Related]
55. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.
Ross W; Rowe T; Glisson B; Yalowich J; Liu L
Cancer Res; 1984 Dec; 44(12 Pt 1):5857-60. PubMed ID: 6094001
[TBL] [Abstract][Full Text] [Related]
56. Topoisomerase-II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA.
Woynarowski JM; Sigmund RD; Beerman TA
Biochim Biophys Acta; 1988 May; 950(1):21-9. PubMed ID: 2833925
[TBL] [Abstract][Full Text] [Related]
57. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
[TBL] [Abstract][Full Text] [Related]
58. Topoisomerase II cleavage in chromatin.
Udvardy A; Schedl P; Sander M; Hsieh TS
J Mol Biol; 1986 Sep; 191(2):231-46. PubMed ID: 3027349
[TBL] [Abstract][Full Text] [Related]
59. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
De Isabella P; Capranico G; Binaschi M; Tinelli S; Zunino F
Mol Pharmacol; 1990 Jan; 37(1):11-6. PubMed ID: 2153905
[TBL] [Abstract][Full Text] [Related]
60. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
